oxonic acid has been researched along with Hyperpigmentation in 2 studies
Oxonic Acid: Antagonist of urate oxidase.
Hyperpigmentation: Excessive pigmentation of the skin, usually as a result of increased epidermal or dermal melanin pigmentation, hypermelanosis. Hyperpigmentation can be localized or generalized. The condition may arise from exposure to light, chemicals or other substances, or from a primary metabolic imbalance.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5 mg/kg/day regimen produced one dead or moribund dog of each sex; black-brown patch (melanin deposition) and inflammatory changes in the eyes and skin; decreased in body weight gains; increases in MCV, MCH, monocyte ratio, and serum protein and uric acid; decreases in lymphocyte ratio and erythrocyte count, hematocrit, hemoglobin, albumin, A/G ratio, cholesterol (esterified, total and free), phospholipids, triglycerides, cholinesterase activity and creatinine; increases in relative liver and adrenal weights." | 3.69 | [A 52-week oral toxicity study of a new antineoplastic agent S-1 in dogs]. ( Enomoto, M; Inoue, H; Kitajima, S; Kobayashi, K; Okamura, T; Watari, N; Yamaguchi, S, 1996) |
| "Unresectable advanced hepatocellular carcinoma is a heterogeneous disease, for which sorafenib is the first targeted agent approved for first-line therapy, and treatment options for patients with sorafenib-refractory advanced hepatocellular carcinoma are limited." | 2.84 | S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial. ( Date, Y; Fang, X; Furuse, J; Hidaka, H; Ikeda, M; Kaneko, S; Kawazoe, S; Kudo, M; Moriguchi, M; Numata, K; Ohkawa, S; Okusaka, T; Sato, Y; Takeuchi, M; Tanaka, H, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kudo, M | 1 |
| Moriguchi, M | 1 |
| Numata, K | 1 |
| Hidaka, H | 1 |
| Tanaka, H | 1 |
| Ikeda, M | 1 |
| Kawazoe, S | 1 |
| Ohkawa, S | 1 |
| Sato, Y | 1 |
| Kaneko, S | 1 |
| Furuse, J | 1 |
| Takeuchi, M | 2 |
| Fang, X | 1 |
| Date, Y | 1 |
| Okusaka, T | 1 |
| Kitajima, S | 1 |
| Okamura, T | 1 |
| Kobayashi, K | 1 |
| Watari, N | 1 |
| Inoue, H | 1 |
| Enomoto, M | 1 |
| Yamaguchi, S | 1 |
1 trial available for oxonic acid and Hyperpigmentation
| Article | Year |
|---|---|
S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Diarrhea; Double-Blind Method; Dru | 2017 |
1 other study available for oxonic acid and Hyperpigmentation
| Article | Year |
|---|---|
[A 52-week oral toxicity study of a new antineoplastic agent S-1 in dogs].
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Blood Chemical Analysis; Blood Coagu | 1996 |